A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

201384 citationsJournal Articlehybrid Open Access

Authors

Kyriakos P. Papadopoulos · South Texas Accelerated Research Therapeutics

Howard A. Burris · Tennessee Oncology

Michael S. Gordon · Pinnacle Oncology Hematology

Peter P. Lee · Providence Saint Joseph Medical Center

Edward A. Sausville · University of Maryland, Baltimore

Peter J. Rosen · Tower Cancer Research Foundation

Amita Patnaik

Abstract

Carfilzomib 20/36 mg/m(2) was well tolerated when administered twice weekly by 2-10-min IV infusion. At this dose and infusion rate, carfilzomib inhibited the proteasome in blood but demonstrated limited antitumor activity in patients with advanced solid tumors.

Topics & Keywords

Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors Ubiquitin and proteasome pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Chemotherapy and Pharmacology

Volume 72, Issue 4, pp. 861-868

DOI: 10.1007/s00280-013-2267-x

Field-Weighted Citation Impact: 6.22